Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 20 11:21AM ET
1.07
Dollar change
+0.03
Percentage change
2.40
%
Index- P/E- EPS (ttm)-1.26 Insider Own28.09% Shs Outstand34.76M Perf Week-2.29%
Market Cap40.05M Forward P/E- EPS next Y-0.21 Insider Trans0.00% Shs Float27.04M Perf Month-0.47%
Income-37.81M PEG- EPS next Q-0.17 Inst Own49.80% Short Float2.13% Perf Quarter-27.05%
Sales0.00M P/S- EPS this Y30.47% Inst Trans-2.92% Short Ratio1.44 Perf Half Y107.52%
Book/sh-0.65 P/B- EPS next Y76.85% ROA-92.81% Short Interest0.57M Perf Year-23.38%
Cash/sh1.30 P/C0.82 EPS next 5Y- ROE-700.45% 52W Range0.47 - 1.82 Perf YTD22.74%
Dividend Est.- P/FCF- EPS past 5Y-77.09% ROI-171.09% 52W High-41.57% Beta2.58
Dividend TTM- Quick Ratio1.71 Sales past 5Y-5.80% Gross Margin57.93% 52W Low126.60% ATR (14)0.09
Dividend Ex-Date- Current Ratio1.71 EPS Y/Y TTM34.43% Oper. Margin0.00% RSI (14)43.42 Volatility5.51% 8.87%
Employees14 Debt/Eq- Sales Y/Y TTM-100.00% Profit Margin- Recom1.00 Target Price5.30
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q36.62% Payout- Rel Volume0.36 Prev Close1.04
Sales Surprise- EPS Surprise-313.56% Sales Q/Q-100.00% EarningsMay 13 AMC Avg Volume399.65K Price1.07
SMA20-3.12% SMA50-15.01% SMA20013.00% Trades Volume46,127 Change2.40%
Date Action Analyst Rating Change Price Target Change
Apr-04-24Initiated Piper Sandler Overweight $9
May-15-24 07:03AM
May-13-24 10:53PM
04:16PM
May-01-24 07:00AM
Apr-29-24 01:37PM
07:03AM Loading…
Apr-10-24 07:03AM
Mar-28-24 10:53PM
04:15PM
Mar-25-24 07:03AM
Mar-14-24 07:03AM
Mar-13-24 07:03AM
Mar-07-24 04:12PM
Mar-04-24 07:03AM
Feb-14-24 07:03AM
Jan-29-24 07:03AM
09:39AM Loading…
Jan-24-24 09:39AM
Jan-23-24 07:03AM
Dec-18-23 07:03AM
Nov-29-23 07:03AM
Nov-14-23 04:15PM
Oct-23-23 07:03AM
Sep-06-23 07:03AM
Aug-29-23 07:03AM
Aug-14-23 05:36PM
Jul-21-23 04:30PM
09:00AM
Jul-20-23 07:03AM
Jul-18-23 07:03AM
Jun-29-23 05:04PM
Jun-16-23 07:38AM
09:00AM Loading…
Jun-09-23 09:00AM
May-17-23 06:03AM
May-16-23 08:29AM
Apr-24-23 07:00AM
Mar-31-23 07:00AM
Mar-08-23 06:04AM
Mar-07-23 09:00AM
Mar-06-23 07:00AM
Mar-03-23 09:15AM
Feb-27-23 07:00AM
Feb-17-23 10:35AM
Feb-06-23 09:59AM
Feb-02-23 08:30AM
Jan-23-23 07:00AM
Jan-05-23 07:00AM
Dec-29-22 11:31AM
Dec-28-22 09:21AM
08:30AM
Dec-22-22 07:00AM
Dec-09-22 08:00AM
Nov-28-22 07:00AM
Nov-21-22 10:32AM
07:00AM
Nov-14-22 07:00AM
Nov-10-22 07:00AM
Nov-08-22 09:00AM
Oct-26-22 08:04AM
Oct-12-22 08:00AM
Sep-29-22 07:00AM
Sep-23-22 09:11AM
Sep-07-22 07:00AM
Sep-06-22 07:00AM
Aug-24-22 07:00AM
Aug-15-22 06:03PM
Jul-26-22 07:00AM
Jul-20-22 07:12AM
Jul-18-22 07:48AM
07:00AM
Jun-29-22 12:00PM
Jun-06-22 08:00AM
Jun-02-22 08:00AM
May-24-22 08:00AM
May-12-22 07:00AM
Apr-14-22 07:10AM
Mar-31-22 07:00AM
Mar-23-22 08:30AM
Mar-03-22 07:00AM
Feb-02-22 07:00AM
Jan-10-22 07:00AM
Nov-29-21 07:00AM
Nov-11-21 09:14AM
Oct-26-21 07:30AM
Sep-15-21 06:17AM
Sep-07-21 06:00AM
Aug-16-21 06:00AM
Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.